Medical News

RSS

Mylan launches generic version of Bristol-Myers Squibb's Paraplatin Injection

Mylan Inc. today announced that it has launched Carboplatin Injection, 50 mg/5 ml, in multi-dose vials, which is the generic version of Bristol-Myers Squibb's Paraplatin® Injection.

9 Jun 2014

UAB ophthalmologists offer tips to prevent firework related injuries

Fourth of July 2013: Family members were shooting fireworks in the backyard of Dianne Peterson's home in Vincent, Alabama, as she walked out of the house.

9 Jun 2014

New methods for detection of fecal pollution in Norwegian watercourses

The Norwegian Institute for Agricultural and Environmental Research, Bioforsk, has tested and implemented a set of methods for the detection of fecal pollution in Norwegian watercourses.

9 Jun 2014

New hippomsg software designed to live "natively" on smartphones and tablets

The No. 1, free medical-texting solution is unveiling a faster platform that handles attachments during a launch party on June 19 near Fenway Park.

9 Jun 2014

Manchester announces multi-year sponsorship deal with Cho-A Pharm

Manchester United has today announced a multi-year sponsorship deal with Korean Pharmaceutical company Cho-A Pharm to become Manchester United's Official Pharmaceuticals partner of in South Korea and Vietnam.

9 Jun 2014

Researchers identify critical weakness of invasive cancer cells

Metastatic cancer cells, which can migrate from primary tumors to seed new malignancies, have thus far been resistant to the current arsenal of anticancer drugs.

9 Jun 2014

Research finding paves way for targeted approaches to treating cancer patients

Twelve years ago, UNC School of Medicine researcher Brian Strahl, PhD, found that a protein called Set2 plays a role in how yeast genes are expressed - specifically how DNA gets transcribed into messenger RNA. Now his lab has found that Set2 is also a major player in DNA repair, a complicated and crucial process that can lead to the development of cancer cells if the repair goes wrong.

9 Jun 2014

Studies stress the importance of vitamin D intake during first year of life

Everyone seems to agree that vitamin D is important throughout life. This is certainly as true in the first year of life as it is later on.

9 Jun 2014

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI).

9 Jun 2014

Accelera signs agreement to complete preclinical studies of Cellectis' UCART19

Cellectis, a leader of allogeneic CAR T-cell therapies, and Accelera, the preclinical CRO (Contract Research Organisation) within the Nerviano Medical Sciences Group, recently signed an agreement to complete the preclinical studies of Cellectis' advanced product candidate, UCART19.

9 Jun 2014

Cegedim Relationship Management releases Life Sciences-specific CRM platform, Mobile Intelligence

Cegedim Relationship Management today announced the availability of the latest release of its Life Sciences-specific Customer Relationship Management (CRM) platform, Mobile Intelligence, which features a groundbreaking, complete, single platform that brings multichannel together, empowering Life Sciences teams to create better customer interactions.

9 Jun 2014

Valeant Pharmaceuticals receives approval from FDA for treatment of onychomycosis

Valeant Pharmaceuticals International, Inc. today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia® (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.

9 Jun 2014

New class of genetic switches gives clues on stem cell development

Case Western Reserve researchers have discovered landmarks within pluripotent stem cells that guide how they develop to serve different purposes within the body.

9 Jun 2014

BIT Group opens new R&D Center of Excellence in the US

BIT Group has announced the opening of its new 22,500 sq. ft. "Center of Excellence for Life Science and IVD Products" for BIT USA.

9 Jun 2014

Cheetah Medical secures initial investment of $5M from growth equity firm, HighCape Partners

Cheetah Medical, Inc., a leader in non-invasive hemodynamic monitoring systems, today announced that it has secured an initial investment of $5 million from HighCape Partners, a firm co-founded by Kevin Rakin, who joined Cheetah Medical's Board of Directors in 2013.

9 Jun 2014

CFI and Group Lamerica sign new agreement

The Center for Innovation of Arlington (CFI) and Group Lamerica has established an agreement for the purpose of extending CFI business development efforts into the Latin American region.

9 Jun 2014

New mathematical models seem to explain processing in medial temporal lobes

When it comes to familiarity, a slew of memories including seemingly unrelated ones can come flooding into the brain, according to mathematical theories called global similarity models.

9 Jun 2014

Co-founder of Avidity Nanomedicines to receive 2014 Prince of Asturias Award

Avidity NanoMedicines LLC, a biopharmaceutical company pioneering a breakthrough approach to the targeted delivery of nucleic acid-based medicines, announced today that its scientific co-founder, Mark E. Davis, Ph.D., will receive the 2014 Prince of Asturias Award for Technical and Scientific Research.

9 Jun 2014

CAHF renews Preferred Provider deal with COMS Interactive

The California Association of Health Facilities (CAHF) has renewed its Preferred Provider relationship with COMS Interactive (COMS or Clinical Outcomes Management Solutions).

9 Jun 2014

Kush Creams to manufacture and distribute medical marijuana product, 5 Hour High

Alternaturals, Inc., Symbol (OTCPink:ANAS) today announced that it has chosen Kush Creams, a Washington based, medical marijuana grower and distributor with award winning strains and products, to manufacture and distribute its long awaited medical marijuana product, 5 Hour High©.

9 Jun 2014